SCHEMBL4292565

SCHEMBL4292565

O=C(Nc1ccccc1N1CCCCC1)c1[c]cccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 6/20 0.59
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
L3MBTL1 Q9Y468 3/20 0.59
TSHR P16473 3/20 0.59
MAPT P10636 3/20 0.59
ALDH1A1 P00352 2/20 0.59
ATM Q13315 2/20 0.59
GAA P10253 2/20 0.59
ALOX15 P16050 1/20 0.59
USP2 O75604 1/20 0.59
GLA P06280 1/20 0.59
HTT P42858 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
CSF1R P07333 3/20 0.58
MAPK1 P28482 2/20 0.57
LMNA P02545 1/20 0.57
POLB P06746 1/20 0.56
PIM1 P11309 2/20 0.55
PIM3 Q86V86 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4537413 0.99 GAA (0.60) NPSR1MEN1KMT2AL3MBTL1TSHR
SCHEMBL4299849 0.87 CHEK1 (0.52) MAPTALDH1A1GAAALOX15SMN1; SMN2
Hydrochloric Acid SCHEMBL2023240 0.76 POLB (0.76) NPSR1MEN1KMT2ATSHRMAPT
SCHEMBL1643994 0.75 NPSR1 (0.68) NPSR1MEN1KMT2AL3MBTL1TSHR
SCHEMBL13167000 0.75 NPSR1 (0.73) NPSR1MEN1KMT2AL3MBTL1TSHR
SCHEMBL4318899 0.75 KCNQ2 (0.68) NPSR1MEN1KMT2AL3MBTL1TSHR
SCHEMBL1439619 0.75 GAA (0.63) NPSR1MEN1KMT2AL3MBTL1TSHR
SCHEMBL22700670 0.74 KMT2A (0.71) NPSR1MEN1KMT2ATSHRMAPT
SCHEMBL3485343 0.74 KMT2A (0.71) NPSR1MEN1KMT2ATSHRMAPT
SCHEMBL13147758 0.74 CSF1R (1.00) NPSR1MEN1KMT2AL3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286779-A1 PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS NOVARTIS AG 2009-11-19 US claimed
EP-2081933-A1 PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS Novartis Ag (CH) 2009-07-29 EP claimed
WO-2008037477-A1 PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-04-03 WO claimed
US-20090286779-A1 PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS NOVARTIS AG 2009-11-19 US disclosed
EP-2081933-A1 PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS Novartis Ag (CH) 2009-07-29 EP disclosed
WO-2008037477-A1 PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286779-A1 PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS ATR, ATM, CHEK1 NPSR1 4117/4885MEN1 2978/4885KMT2A 1457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.